Founder Tu Zhiliang of GUSHENGTANG (02273) has been honored as one of the "TOP100 Most Influential Chinese Elite" in the 2024 Forbes China.

Recently, the results of the "2024 Forbes China's Most Influential Chinese Elite TOP100" selection were officially announced, with Tu Zhiliang, founder and chairman of GUSHENGTANG (02273), being recognized as a pioneer and innovator in the traditional Chinese medicine industry. His achievements not only serve as a role model for Chinese people worldwide but also showcase the innovative power of Chinese medicine services to the world. In the context of globalization, Chinese elites have shown remarkable resilience and perseverance in the face of uncertainty, with their influence on the international stage becoming increasingly significant. This selection identified 100 outstanding Chinese representatives in two categories, "Influence" and "Growth". The selected individuals under "Influence" category have achieved significant accomplishments this year and have demonstrated strong influence in their respective industries worldwide. As the founder and leader of GUSHENGTANG Chinese medicine, Mr. Tu Zhiliang established GUSHENGTANG in 2010 and, after more than 10 years of hard work and dedication, led the company to a successful listing on the main board of the Hong Kong Stock Exchange in 2021, making GUSHENGTANG the "first stock of Chinese medicine services". With his outstanding leadership, innovative spirit, and keen business acumen, Mr. Tu not only achieved success in the business model but also accelerated the modernization of traditional Chinese medicine, making significant contributions to the digital development and high-quality international expansion of Chinese medicine. The establishment of GUSHENGTANG has allowed traditional Chinese medicine practitioners to feel a sense of dignity, value, and historical significance. Mr. Tu Zhiliang has addressed the issue of insufficient supply of quality Chinese medicine practitioners by inviting renowned veteran Chinese medicine practitioners to provide services at grassroots medical facilities. This model has paved the way for the chain, group, and brand development of privately-run medical institutions. Currently, GUSHENGTANG has 74 offline Chinese medicine clinics in 20 cities domestically and internationally (including Singapore), and its online platform service network covers over 340 cities including Beijing, Shanghai, Guangzhou, Shenzhen, and Suzhou. By integrating online and offline services, GUSHENGTANG enables more people to access high-quality Chinese medicine services conveniently, fostering a growing preference and trust in Chinese medicine among the public. Furthermore, Mr. Tu Zhiliang has innovatively proposed a pathway for advancing from clinical prescriptions to in-house preparations and further to innovative Chinese patent medicines. GUSHENGTANG has successfully developed 10 in-house preparations, accelerating the productization and standardization of medical and health solutions, ensuring better inheritance of renowned Chinese medicine formulas and practitioners. With a global perspective, Mr. Tu Zhiliang injects enormous momentum for GUSHENGTANG's international development. GUSHENGTANG has acquired the 100% equity of Baozhongtang in Singapore, taking the first step towards the internationalization of Chinese medicine. In the ever-changing international market, Mr. Tu has made strategic considerations for the company's overseas expansion. He believes that by leveraging the advantages of scale development and cross-regional operations, GUSHENGTANG can further promote the internationalization of Chinese medicine services and meet the growing global demand for Chinese medicine treatment and health services. In addition to his busy work schedule, Mr. Tu Zhiliang also holds multiple important social positions and provides advice and suggestions for the development of the Chinese medicine industry. He serves as the Chairman of the Chinese Medical Pavilion Community of the Chinese Association of Traditional Chinese Medicine, Executive Director of the Chinese Association of Traditional Chinese Medicine, Vice Chairman of the Working Committee of the World Federation of Chinese Medicine Associations, Deputy Director of the Reform and Development Research Branch of the Chinese Association of Traditional Chinese Medicine, Member of the 13th CPPCC Guangdong Provincial Committee, Advisor of the Chinese Medicine Medical Insurance Policy Research Special Committee of the Guangdong Pharmaceutical Price Association, and has received various industry awards such as the "Meritorious Figure in the Medical Pavilion Industry for the 40th Anniversary of Reform and Opening Up," "National Meritorious Figure in the Medical Pavilion Industry," and "2024 Outstanding Influential Entrepreneur."